| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (NCT01810913) | National Cancer Institute (NCI) | 2013-03-22 |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma (NCT01771107) | National Cancer Institute (NCI) | 2013-03-08 |
| Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing (NCT01730118) | National Cancer Institute (NCI) | 2013-03-04 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma (NCT01814046) | National Cancer Institute (NCI) | 2013-03-01 |
| Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery (NCT01802320) | National Cancer Institute (NCI) | 2013-03-01 |
| Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer (NCT01727076) | National Cancer Institute (NCI) | 2013-02-15 |
| Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas (NCT01794104) | National Cancer Institute (NCI) | 2013-02-15 |
| Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT01708954) | National Cancer Institute (NCI) | 2013-02-13 |
| Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (NCT01802333) | National Cancer Institute (NCI) | 2013-02-12 |
| Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (NCT01767194) | National Cancer Institute (NCI) | 2013-02-12 |
| Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples (NCT01793545) | National Cancer Institute (NCI) | 2013-02-11 |
| Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma (NCT01711554) | National Cancer Institute (NCI) | 2013-02-04 |
| Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01780662) | National Cancer Institute (NCI) | 2013-01-31 |
| Rifaximin for Chronic Immune Activation in People With HIV (NCT01866826) | National Cancer Institute (NCI) | 2013-01-18 |
| Cabozantinib for Adults With Advanced Soft Tissue Sarcoma (NCT01755195) | National Cancer Institute (NCI) | 2013-01-15 |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery (NCT01783171) | National Cancer Institute (NCI) | 2013-01-15 |
| Colon Cancer Study of Fecal Samples in Shanghai, China (NCT01778595) | National Cancer Institute (NCI) | 2013-01-08 |
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery (NCT01859182) | National Cancer Institute (NCI) | 2013-01-01 |
| Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma (NCT01861301) | National Cancer Institute (NCI) | 2013-01-01 |
| Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer (NCT01776008) | National Cancer Institute (NCI) | 2013-01-01 |
| AZD1775 for Advanced Solid Tumors (NCT01748825) | National Cancer Institute (NCI) | 2012-12-19 |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (NCT01711528) | National Cancer Institute (NCI) | 2012-12-19 |
| Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01757639) | National Cancer Institute (NCI) | 2012-12-14 |
| Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer (NCT01749397) | National Cancer Institute (NCI) | 2012-12-07 |
| Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT01749384) | National Cancer Institute (NCI) | 2012-12-06 |
| Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer (NCT01622868) | National Cancer Institute (NCI) | 2012-12-06 |
| Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (NCT01693783) | National Cancer Institute (NCI) | 2012-12-03 |
| TRC105 for Recurrent Glioblastoma (NCT01778530) | National Cancer Institute (NCI) | 2012-12-01 |
| Improving Cervical Cancer Screening Among HIV-Infected Women in India (NCT02247999) | National Cancer Institute (NCI) | 2012-11-28 |
| Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (NCT01729806) | National Cancer Institute (NCI) | 2012-11-19 |
| Perspective-taking, and Examining the Clinical Trial Informed Consent Process (NCT01778582) | National Cancer Institute (NCI) | 2012-11-15 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors (NCT01709435) | National Cancer Institute (NCI) | 2012-11-14 |
| Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT01716715) | National Cancer Institute (NCI) | 2012-11-06 |
| Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (NCT01727089) | National Cancer Institute (NCI) | 2012-11-01 |
| Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme (NCT01648348) | National Cancer Institute (NCI) | 2012-11-01 |
| Ruxolitinib for Adult T-Cell Leukemia (NCT01712659) | National Cancer Institute (NCI) | 2012-10-26 |
| Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer (NCT01711541) | National Cancer Institute (NCI) | 2012-10-22 |
| Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas (NCT01434602) | National Cancer Institute (NCI) | 2012-10-02 |
| Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer (NCT01711515) | National Cancer Institute (NCI) | 2012-10-01 |
| Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors (NCT01725191) | National Cancer Institute (NCI) | 2012-10-01 |
| Imaging Studies of Kidney Cancer Using 18F-VM4-037 (NCT01712685) | National Cancer Institute (NCI) | 2012-10-01 |
| Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors (NCT01217450) | National Cancer Institute (NCI) | 2012-10-01 |
| Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer (NCT01642251) | National Cancer Institute (NCI) | 2012-09-28 |
| Tissue Collection for Studies of Lymph Cancer (NCT01676805) | National Cancer Institute (NCI) | 2012-09-21 |
| Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1) (NCT01702922) | National Cancer Institute (NCI) | 2012-09-13 |
| Cabozantinib for Advanced Urothelial Cancer (NCT01688999) | National Cancer Institute (NCI) | 2012-09-11 |
| Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer (NCT01683994) | National Cancer Institute (NCI) | 2012-09-07 |
| Mithramycin for Lung, Esophagus, and Other Chest Cancers (NCT01624090) | National Cancer Institute (NCI) | 2012-09-06 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery (NCT01705340) | National Cancer Institute (NCI) | 2012-09-01 |
| Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (NCT01695941) | National Cancer Institute (NCI) | 2012-08-31 |
| Pomalidomide for Chronic Graft-versus-Host Disease (NCT01688466) | National Cancer Institute (NCI) | 2012-08-30 |
| GRN1005 for Brain Metastases From Breast or Lung Cancer (NCT01679743) | National Cancer Institute (NCI) | 2012-08-29 |
| Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (NCT01653028) | National Cancer Institute (NCI) | 2012-08-22 |
| Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer (NCT01624441) | National Cancer Institute (NCI) | 2012-08-21 |
| Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (NCT01696955) | National Cancer Institute (NCI) | 2012-08-20 |
| Lenalidomide Maintenance Therapy for Multiple Myeloma (NCT01675141) | National Cancer Institute (NCI) | 2012-08-20 |
| Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery (NCT01688973) | National Cancer Institute (NCI) | 2012-08-20 |
| Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (NCT01681368) | National Cancer Institute (NCI) | 2012-08-15 |
| Self-Affirmation and Response to Health Risk Information (NCT01668771) | National Cancer Institute (NCI) | 2012-08-11 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery (NCT01575548) | National Cancer Institute (NCI) | 2012-08-08 |
| Validating Pain Scales in Children and Young Adults (NCT01639950) | National Cancer Institute (NCI) | 2012-08-06 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus (NCT01637961) | National Cancer Institute (NCI) | 2012-08-01 |
| ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer (NCT01675128) | National Cancer Institute (NCI) | 2012-08-01 |
| Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation (NCT01447355) | National Cancer Institute (NCI) | 2012-08-01 |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer (NCT01664182) | National Cancer Institute (NCI) | 2012-08-01 |
| Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy (NCT01658943) | National Cancer Institute (NCI) | 2012-08-01 |
| MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma (NCT01660997) | National Cancer Institute (NCI) | 2012-07-30 |
| Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT01660971) | National Cancer Institute (NCI) | 2012-07-30 |
| Natural History Study of Children and Adults With Medullary Thyroid Cancer (NCT01660984) | National Cancer Institute (NCI) | 2012-07-30 |
| Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer (NCT01638546) | National Cancer Institute (NCI) | 2012-07-27 |
| Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors (NCT01654965) | National Cancer Institute (NCI) | 2012-07-24 |
| Collecting Solid Tumor Tissue to Identify New Treatments (NCT01658917) | National Cancer Institute (NCI) | 2012-07-24 |
| Biomarkers for Breast Cancer Risk in African American Women (NCT01736306) | National Cancer Institute (NCI) | 2012-07-23 |
| Testing the FLASHE Survey (NCT01661036) | National Cancer Institute (NCI) | 2012-07-23 |
| Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma (NCT01604772) | National Cancer Institute (NCI) | 2012-07-23 |
| The Ghana Breast Health Study (NCT01661023) | National Cancer Institute (NCI) | 2012-07-19 |
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance (NCT01647165) | National Cancer Institute (NCI) | 2012-07-11 |
| Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma (NCT01553149) | National Cancer Institute (NCI) | 2012-07-05 |
| Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma (NCT01658904) | National Cancer Institute (NCI) | 2012-07-01 |
| Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer (NCT01688609) | National Cancer Institute (NCI) | 2012-07-01 |
| Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery (NCT01623869) | National Cancer Institute (NCI) | 2012-07-01 |
| Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (NCT01643278) | National Cancer Institute (NCI) | 2012-07-01 |
| Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma (NCT01593696) | National Cancer Institute (NCI) | 2012-06-29 |
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (NCT01614795) | National Cancer Institute (NCI) | 2012-06-18 |
| Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain (NCT01633008) | National Cancer Institute (NCI) | 2012-06-15 |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors (NCT01609790) | National Cancer Institute (NCI) | 2012-06-04 |
| Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus (NCT01447927) | National Cancer Institute (NCI) | 2012-06-01 |
| High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma (NCT01378481) | National Cancer Institute (NCI) | 2012-06-01 |
| Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (NCT01572480) | National Cancer Institute (NCI) | 2012-05-29 |
| Vorinostat in Treating Patients With Metastatic Melanoma of the Eye (NCT01587352) | National Cancer Institute (NCI) | 2012-05-29 |
| Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis (NCT01441089) | National Cancer Institute (NCI) | 2012-05-21 |
| CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII (NCT01454596) | National Cancer Institute (NCI) | 2012-05-16 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT01585805) | National Cancer Institute (NCI) | 2012-05-15 |
| Sunitinib for Advanced Thymus Cancer Following Earlier Treatment (NCT01621568) | National Cancer Institute (NCI) | 2012-05-15 |
| Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma (NCT01610570) | National Cancer Institute (NCI) | 2012-05-10 |
| 18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma (NCT01610544) | National Cancer Institute (NCI) | 2012-05-10 |
| CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer (NCT01583686) | National Cancer Institute (NCI) | 2012-05-04 |
| Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy (NCT01595074) | National Cancer Institute (NCI) | 2012-05-01 |
| Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery (NCT01625156) | National Cancer Institute (NCI) | 2012-05-01 |